At this very early point in the emerging 2019-nCoV outbreak, knowledge about the virus is insufficient to predict what shape that outbreak will ultimately take.
The drug screens prompted by the SARS and MERS outbreaks have been useful for quickly identifying drug candidates. But in terms of their epidemiology, “SARS and MERS were different from this coronavirus,” Allison McGeer explained at a Feb. 3 webinar by Evercore ISI.
Keeping you up to date on recent developments in oncology, including: Study bolsters case for maximal resection for glioblastoma; CD47 knockout improves antitumor vaccine; Distinguishing real from backseat drivers; Protons come to American state of Alabama.
For depression, and other mental health disorders, the era of precision medicine has yet to arrive.
Symptoms are “very poorly reflective of the underlying biology,” Amit Etkin told BioWorld. Depression can manifest through multiple different symptoms that differ both between and within cultures.
Inclisiran’s inclusion on the 2020 Cortellis Drugs to Watch list is an example of target discovery possibilities hiding in plain sight – if companies and institutions are willing to put effort into increasing sample diversity in genomic research.
“Lack of knowledge is the true bottleneck to clinical translation. We need to stop telling basic scientists, especially trainees, that their work’s value lies in its translatability.” That is the unexpected advice of none other than William Kaelin Jr., whose scientific discoveries have proved to be both top-rate science and very translatable indeed. His work, for which Kaelin has won the 2019 Nobel Prize in Physiology or Medicine and a host of other awards, has enabled the development of multiple therapies targeting anemia and cancer, including vadadustat.
Keeping you up to date on recent developments in neurology, including: Online therapy for lingering depression could fill gap in care; UTHealth develops technology to differentiate between PD and multiple system atrophy; Myelin is deregulated in autism spectrum disorder.
BioWorld looks at translational medicine, including: CD47 knockout improves antitumor vaccine; Multiple edits make for durable T cells; Endothelial cells have functional deficits in progeria; Myelin is deregulated in autism spectrum disorder; More enhancers suggest more pathogenicity: study; Just the vesicles, please; Distinguishing real from backseat drivers; Blocking bad bone; Plexin D1 is receptor and mechanosensor in 1; Monocytes have it both ways in DMD.
Keeping you up to date on recent developments in diagnostics, including: Raman spectroscopy to monitor blood glucose; A score to predict progressive chronic liver disease; From African genomes, big insights with small sample size.
The drug screens prompted by the SARS and MERS outbreaks have been useful for quickly identifying drug candidates. But in terms of their epidemiology, “SARS and MERS were different from this coronavirus,” Allison McGeer explained at a Feb. 3 webinar by Evercore ISI.
